Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Gastric Antisecretory Drug Market In 2029?
Over the past few years, the market size of gastric antisecretory drugs has seen significant expansion. The market is projected to climb from $14.87 billion in 2024 to $15.63 billion in 2025, bolstered by a compound annual growth rate (CAGR) of 5.1%. The historic growth of this market can be ascribed to factors like increased stress levels and passive lifestyles, a surge in helicobacter pylori infections, encouraging government health policies, the expansion of medical tourism, and the growth of e-commerce and online pharmacies.
In the coming years, the gastric antisecretory drug market is forecasted to experience substantial growth. It is anticipated to swell to a value of $19.56 billion by 2029, with a compound annual growth rate (CAGR) of 5.8%. This anticipated growth in the coming years can be linked to the increasing frequency of gastrointestinal disorders, an aging population, greater public awareness regarding digestive health, an expanding health care infrastructure, and the rising consumption of rapidly prepared and processed foods. The forecast period is expected to see trends such as extensive usage of NSAIDs, the ability to purchase antisecretory drugs over-the-counter (OTC), advancements in the technology of drug delivery systems, availability of generic versions of these drugs, and progress in creating combination therapies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24222&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Gastric Antisecretory Drug Market?
An increase in cases of gastrointestinal disorders is expected to fuel the expansion of the gastric antisecretory drug market in the near future. These disorders can disturb the digestive system, including the stomach, intestines, and related organs, manifesting symptoms such as pain, bloating, and irregular bowel movements. This increase can be attributed primarily to unhealthy eating practices where the consumption of processed foods and lack of adequate fiber messes up gut microbiota and hampers digestion. Gastric antisecretory medications are necessary, as the excess production of stomach acid can destroy the defensive lining of the gastrointestinal tract, causing irritation or harm. These drugs mitigate this by cutting down the acid output. For example, data from ScienceDirect, a bibliographic database from the US, showed that approximately 23.5 million gastrointestinal endoscopies were conducted in 2022 as reported in May 2025. As such, this surge in gastrointestinal disorders is expected to act as a catalyst for the gastric antisecretory drug market’s growth.
Which Key Market Segments Comprise the Gastric Antisecretory Drug Market and Drive Its Revenue Growth?
The gastric antisecretory drug market covered in this report is segmented –
1) By Drug Class: Proton Pump Inhibitors (PPIs), H2 Receptor Antagonists, Antacids, Prostaglandin Analogs
2) By Route Of Administration: Oral, Intravenous, Topical
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By Application: Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Zollinger-Ellison Syndrome, Other Applications
Subsegments:
1) By Proton Pump Inhibitors (PPIs): Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole, Dexlansoprazole
2)By H2 Receptor Antagonists: Ranitidine, Famotidine, Cimetidine, Nizatidine
3) By Antacids: Magnesium Hydroxide, Calcium Carbonate, Aluminum Hydroxide, Sodium Bicarbonate, Combination Antacids
4) By Prostaglandin Analogs: Misoprostol, Enprostil
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24222&type=smp
Which Areas Are Leading Regions in the Gastric Antisecretory Drug Market Expansion Across the Globe?
North America was the largest region in the gastric antisecretory drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric antisecretory drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theGastric Antisecretory Drug Market Direction?
Leading companies in the gastric antisecretory drug market are prioritizing the development of cutting-edge products like antisecretory compounds for a more extended and effective relief. These compounds are chemical substances that decrease or prevent the secretion of body fluids, notably gastric acid, by targeting specific cellular receptors or pathways. For example, in June 2024, Rabeprazole + Levosulpiride SR Capsules, a new formulation for gastrointestinal patients, was introduced by Akums Drugs and Pharmaceuticals, a pharmaceutical company based in India. This innovative formulation combines rabeprazole sodium, which is a powerful antisecretory agent that selectively obstructs the H?/K? ATPase in gastric parietal cells, and levosulpiride, recognized for its antiemetic and central antidopaminergic properties. The capsule contains 40 mg of enteric-coated rabeprazole and 75 mg of sustained-release levosulpiride, which assures targeted and long-lasting therapeutic benefits. It employs a dual mechanism to address the regulation of gastrointestinal motility and acid suppression.
View the full report here:
https://www.thebusinessresearchcompany.com/report/gastric-antisecretory-drug-global-market-report
How Is the Gastric Antisecretory Drug Market Conceptually Defined?
A gastric antisecretory drug is a type of medication designed to reduce gastric acid production in the stomach. These drugs work by inhibiting specific pathways or receptors in stimulating acid secretion, thereby decreasing the overall acidity of the stomach contents. A gastric antisecretory drug helps maintain a more neutral pH in the gastric environment, which can be beneficial for protecting the stomach lining and supporting digestive balance.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24222
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model